Published in J Pharmacol Exp Ther on June 27, 2006
Discovery of heterobicyclic templates for novel metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett (2007) 1.54
Glutamatergic modulators: the future of treating mood disorders? Harv Rev Psychiatry (2010) 1.42
Reduced metabotropic glutamate receptor 5 density in major depression determined by [(11)C]ABP688 PET and postmortem study. Am J Psychiatry (2011) 1.34
Review of pharmacological treatment in mood disorders and future directions for drug development. Neuropsychopharmacology (2011) 1.28
Novel glutamatergic agents for major depressive disorder and bipolar disorder. Pharmacol Biochem Behav (2011) 1.24
Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur Arch Psychiatry Clin Neurosci (2013) 1.24
Metabotropic glutamate receptor 5 (mGluR5) regulation of ethanol sedation, dependence and consumption: relationship to acamprosate actions. Int J Neuropsychopharmacol (2008) 1.21
Development of allosteric modulators of GPCRs for treatment of CNS disorders. Neurobiol Dis (2013) 1.20
The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders. Neuroscientist (2009) 1.13
Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders. Curr Pharm Des (2009) 1.08
Metabotropic glutamate receptor subtype 5 antagonism in learning and memory. Eur J Pharmacol (2010) 1.07
Radiodefluorination of 3-fluoro-5-(2-(2-[18F](fluoromethyl)-thiazol-4-yl)ethynyl)benzonitrile ([18F]SP203), a radioligand for imaging brain metabotropic glutamate subtype-5 receptors with positron emission tomography, occurs by glutathionylation in rat brain. J Pharmacol Exp Ther (2008) 1.07
From synapse to nucleus: novel targets for treating depression. Neuropharmacology (2009) 1.06
Design and synthesis of novel heterobiaryl amides as metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett (2007) 1.04
Novel glutamatergic drugs for the treatment of mood disorders. Neuropsychiatr Dis Treat (2013) 1.02
Open questions in current models of antidepressant action. Br J Pharmacol (2010) 0.99
The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence. Pharmacol Ther (2013) 0.98
Sex differences in glutamate receptor gene expression in major depression and suicide. Mol Psychiatry (2015) 0.96
Niemann-pick C1 is essential for ebolavirus replication and pathogenesis in vivo. MBio (2015) 0.93
Potent mGluR5 antagonists: pyridyl and thiazolyl-ethynyl-3,5-disubstituted-phenyl series. Bioorg Med Chem Lett (2011) 0.91
Allosteric modulation of metabotropic glutamate receptors. Adv Pharmacol (2011) 0.91
Bipolar disorder: candidate drug targets. Mt Sinai J Med (2008) 0.90
In vivo positron emission tomography imaging with [¹¹C]ABP688: binding variability and specificity for the metabotropic glutamate receptor subtype 5 in baboons. Eur J Nucl Med Mol Imaging (2011) 0.89
Involvement of metabotropic glutamate receptor 5 in brain reward deficits associated with cocaine and nicotine withdrawal and somatic signs of nicotine withdrawal. Psychopharmacology (Berl) (2011) 0.88
Metabotropic glutamate receptor subtype 5: molecular pharmacology, allosteric modulation and stimulus bias. Br J Pharmacol (2015) 0.88
Therapeutic potential of metabotropic glutamate receptor modulators. Curr Neuropharmacol (2012) 0.85
Alteration by p11 of mGluR5 localization regulates depression-like behaviors. Mol Psychiatry (2015) 0.84
Molecular Insights into Metabotropic Glutamate Receptor Allosteric Modulation. Mol Pharmacol (2015) 0.83
mGluR5 in the nucleus accumbens is critical for promoting resilience to chronic stress. Nat Neurosci (2015) 0.81
Potential of Glutamate-Based Drug Discovery for Next Generation Antidepressants. Pharmaceuticals (Basel) (2015) 0.80
Metabotropic glutamate receptors: potential drug targets for psychiatric disorders. Open Med Chem J (2010) 0.79
Characterization of brain mGluR5 binding in a pilot study of late-life major depressive disorder using positron emission tomography and [(11)C]ABP688. Transl Psychiatry (2015) 0.78
Rethinking metabotropic glutamate receptor 5 pathological findings in psychiatric disorders: implications for the future of novel therapeutics. BMC Psychiatry (2014) 0.78
Proof of concept trials in bipolar disorder and major depressive disorder: a translational perspective in the search for improved treatments. Depress Anxiety (2011) 0.77
VU0477573: Partial Negative Allosteric Modulator of the Subtype 5 Metabotropic Glutamate Receptor with In Vivo Efficacy. J Pharmacol Exp Ther (2015) 0.77
The antidepressant-like action of mGlu5 receptor antagonist, MTEP, in the tail suspension test in mice is serotonin dependent. Psychopharmacology (Berl) (2014) 0.77
Tyrosine phosphorylation of glutamate receptors by non-receptor tyrosine kinases: roles in depression-like behavior. Neurotransmitter (Houst) (2016) 0.77
Glutamate and Gamma-Aminobutyric Acid Systems in the Pathophysiology of Major Depression and Antidepressant Response to Ketamine. Biol Psychiatry (2016) 0.77
Transcriptional profiling of the rat frontal cortex following administration of the mGlu5 receptor antagonists MPEP and MTEP. Eur J Pharmacol (2008) 0.77
Overexpression of Adenosine A2A Receptors in Rats: Effects on Depression, Locomotion, and Anxiety. Front Psychiatry (2014) 0.76
Metabotropic glutamate receptor 5 - a promising target in drug development and neuroimaging. Eur J Nucl Med Mol Imaging (2016) 0.76
Preclinical findings predicting efficacy and side-effect profile of LY2940094, an antagonist of nociceptin receptors. Pharmacol Res Perspect (2016) 0.75
The Emerging Role of Metabotropic Glutamate Receptors in the Pathophysiology of Chronic Stress-Related Disorders. Curr Neuropharmacol (2016) 0.75
Synthesis and Evaluation of Metabotropic Glutamate Receptor Subtype 5 Antagonists Based on Fenobam(). ACS Med Chem Lett (2011) 0.75
Modulation of the activity of N-methyl-d-aspartate receptors as a novel treatment option for depression: current clinical evidence and therapeutic potential of rapastinel (GLYX-13). Neuropsychiatr Dis Treat (2017) 0.75
Emotional Impairment and Persistent Upregulation of mGlu5 Receptor following Morphine Abstinence: Implications of an mGlu5-MOPr Interaction. Int J Neuropsychopharmacol (2016) 0.75
Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior. J Pharmacol Exp Ther (2005) 1.87
Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2- trifluoroethylsulfonyl)pyrid-3-ylmethylamine. J Med Chem (2003) 1.53
The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. Br J Pharmacol (2003) 1.33
Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac). Proc Natl Acad Sci U S A (2002) 1.28
In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders. Psychopharmacology (Berl) (2007) 1.24
Mood disorders: regulation by metabotropic glutamate receptors. Biochem Pharmacol (2007) 1.22
Decreases in nestlet shredding of mice by serotonin uptake inhibitors: comparison with marble burying. Life Sci (2005) 1.15
Comparison of rat dopamine D2 receptor occupancy for a series of antipsychotic drugs measured using radiolabeled or nonlabeled raclopride tracer. Life Sci (2006) 1.10
AMPA receptor potentiators: application for depression and Parkinson's disease. Curr Drug Targets (2007) 1.08
A role for AMPA receptors in mood disorders. Biochem Pharmacol (2006) 1.06
Melanin-concentrating hormone-1 receptor modulates neuroendocrine, behavioral, and corticolimbic neurochemical stress responses in mice. Neuropsychopharmacology (2006) 1.06
Caffeine potentiates the discriminative-stimulus effects of nicotine in rats. Psychopharmacology (Berl) (2002) 1.05
Enhancement of antidepressant potency by a potentiator of AMPA receptors. Cell Mol Neurobiol (2003) 1.04
Use of LC/MS to assess brain tracer distribution in preclinical, in vivo receptor occupancy studies: dopamine D2, serotonin 2A and NK-1 receptors as examples. Life Sci (2005) 1.04
Biochemical and behavioral evidence for antidepressant-like effects of 5-HT6 receptor stimulation. J Neurosci (2007) 1.00
Antidepressant-like effects of an AMPA receptor potentiator under a chronic mild stress paradigm. Int J Neuropsychopharmacol (2010) 0.90
Protective efficacy of neuroactive steroids against cocaine kindled-seizures in mice. Eur J Pharmacol (2003) 0.90
Anxiolytic-like effects through a GLUK5 kainate receptor mechanism. Neuropharmacology (2007) 0.89
Pharmacological and genetic manipulation of kappa opioid receptors: effects on cocaine- and pentylenetetrazol-induced convulsions and seizure kindling. Neuropharmacology (2006) 0.88
Analgesic effects of serotonergic, noradrenergic or dual reuptake inhibitors in the carrageenan test in rats: evidence for synergism between serotonergic and noradrenergic reuptake inhibition. Neuropharmacology (2006) 0.87
Configuring radioligand receptor binding assays for HTS using scintillation proximity assay technology. Methods Mol Biol (2002) 0.86
Preclinical evaluation of melanin-concentrating hormone receptor 1 antagonism for the treatment of obesity and depression. J Pharmacol Exp Ther (2009) 0.86
Modulation of lateral perforant path excitatory responses by metabotropic glutamate 8 (mGlu8) receptors. Neuropharmacology (2002) 0.84
Genetic deletion of the norepinephrine transporter decreases vulnerability to seizures. Neurosci Lett (2005) 0.84
In vitro and in vivo studies in rats with LY293558 suggest AMPA/kainate receptor blockade as a novel potential mechanism for the therapeutic treatment of anxiety disorders. Psychopharmacology (Berl) (2006) 0.83
Discovery of a novel series of orally active nociceptin/orphanin FQ (NOP) receptor antagonists based on a dihydrospiro(piperidine-4,7'-thieno[2,3-c]pyran) scaffold. J Med Chem (2014) 0.83
Pharmacological modulation of GABA(B) receptors affects cocaine-induced seizures in mice. Psychopharmacology (Berl) (2004) 0.83
Neurotensin negatively modulates Akt activity in neurotensin receptor-1-transfected AV12 cells. J Cell Biochem (2004) 0.82
Glucose metabolic trapping in mouse arteries: nonradioactive assay of atherosclerotic plaque inflammation applicable to drug discovery. PLoS One (2012) 0.82
Chlormethiazole potentiates the discriminative stimulus effects of methamphetamine in rats. Eur J Pharmacol (2004) 0.82
Constitutive deletion of the serotonin-7 (5-HT(7)) receptor decreases electrical and chemical seizure thresholds. Epilepsy Res (2007) 0.81
Systemic administration of the potent mGlu8 receptor agonist (S)-3,4-DCPG induces c-Fos in stress-related brain regions in wild-type, but not mGlu8 receptor knockout mice. Neuropharmacology (2003) 0.81
mGlu5 receptor deletion reduces relapse to food-seeking and prevents the anti-relapse effects of mGlu5 receptor blockade in mice. Life Sci (2011) 0.80
Attenuation of the stimulant and convulsant effects of cocaine by 17-substituted-3-hydroxy and 3-alkoxy derivatives of dextromethorphan. Pharmacol Biochem Behav (2003) 0.80
A parametric analysis of punishment frequency as a determinant of the response to chlordiazepoxide in the Vogel conflict test in rats. Pharmacol Biochem Behav (2007) 0.77
Effects of cocaine-kindling on the expression of NMDA receptors and glutamate levels in mouse brain. Neurochem Res (2010) 0.77
Hedonic and motivational responses to food reward are unchanged in rats with neuropathic pain. Pain (2016) 0.76
A Selective Nociceptin Receptor Antagonist to Treat Depression: Evidence from Preclinical and Clinical Studies. Neuropsychopharmacology (2016) 0.76
mGlu5 receptor deletion does not confer seizure protection to mice. Life Sci (2008) 0.76
Effects of dopamine D1 receptor agonists in rats trained to discriminate dihydrexidine. Psychopharmacology (Berl) (2006) 0.75
Multiple dopamine receptors mediate the discriminative stimulus effects of dihydrexidine in rats. Behav Pharmacol (2011) 0.75
How natural is it for nature to help with major depressive disorder? CNS Neurol Disord Drug Targets (2013) 0.75
Structural Determinants of the γ-8 TARP Dependent AMPA Receptor Antagonist. ACS Chem Neurosci (2017) 0.75